Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Volkin

Showing results (161-170 of 175) with videos related to

Pageof 18
Sort By:
Journal of Pharmaceutical Sciences|August 1, 2022
Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation DevelopmentKaushal Jerajani, Ying Wan, John M Hickey, et al.
Human Vaccines & Immunotherapeutics|June 6, 2022
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvantsSakshi Bajoria, Kawaljit Kaur, Ozan S Kumru, et al.
Journal of Pharmaceutical Sciences|December 7, 2020
Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine AntigensNishant Sawant, Kawaljit Kaur, David A Holland, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2023
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Nature Communications|April 17, 2023
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Microbial Cell Factories|May 2, 2021
Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirusNeil C Dalvie, Joseph R Brady, Laura E Crowell, et al.
Journal of Virology|June 14, 2003
Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag geneDanilo R Casimiro, Aimin Tang, Ling Chen, et al.
Vaccine|January 7, 2023
Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variantsSergio A Rodriguez-Aponte, Neil C Dalvie, Ting Y Wong, et al.
Biorxiv : the Preprint Server for Biology|July 20, 2021
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primatesNeil C Dalvie, Lisa H Tostanoski, Sergio A Rodriguez-Aponte, et al.
Journal of Virology|May 14, 2003
Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag geneDanilo R Casimiro, Ling Chen, Tong-Ming Fu, et al.
Pageof 18

Showing results (161-170 of 175) with videos related to

Sort By:
Pageof 18
Journal of Pharmaceutical Sciences|August 1, 2022
Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation DevelopmentKaushal Jerajani, Ying Wan, John M Hickey, et al.
Human Vaccines & Immunotherapeutics|June 6, 2022
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvantsSakshi Bajoria, Kawaljit Kaur, Ozan S Kumru, et al.
Journal of Pharmaceutical Sciences|December 7, 2020
Rapid Developability Assessments to Formulate Recombinant Protein Antigens as Stable, Low-Cost, Multi-Dose Vaccine Candidates: Case-Study With Non-Replicating Rotavirus (NRRV) Vaccine AntigensNishant Sawant, Kawaljit Kaur, David A Holland, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2023
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Nature Communications|April 17, 2023
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primatesPayton A-B Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, et al.
Microbial Cell Factories|May 2, 2021
Molecular engineering improves antigen quality and enables integrated manufacturing of a trivalent subunit vaccine candidate for rotavirusNeil C Dalvie, Joseph R Brady, Laura E Crowell, et al.
Journal of Virology|June 14, 2003
Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag geneDanilo R Casimiro, Aimin Tang, Ling Chen, et al.
Vaccine|January 7, 2023
Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variantsSergio A Rodriguez-Aponte, Neil C Dalvie, Ting Y Wong, et al.
Biorxiv : the Preprint Server for Biology|July 20, 2021
A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primatesNeil C Dalvie, Lisa H Tostanoski, Sergio A Rodriguez-Aponte, et al.
Journal of Virology|May 14, 2003
Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag geneDanilo R Casimiro, Ling Chen, Tong-Ming Fu, et al.
Pageof 18